Gastrointestinal involvement in EMP remains extremely rare. Given the potential sensitivity of t(11;14)-positive plasma cell neoplasms to BCL-2 inhibition, agents such as venetoclax may represent promising alternatives, particularly in refractory cases. The gene discussed is BCL2; the disease is plasma cell neoplasm.